DOCS · Doximity, Inc.
$20.45
-0.20% last session
End-of-day data · updated 2026-07-25
Market cap
$4B
Enterprise value
$3B
Trailing P/E
20.8
Forward P/E
12.8
Dividend yield
—
Beta
1.29
Avg volume
4M
Employees
1K
2D change
-0.15%
5D change
-6.03%
10D change
-8.27%
30D change
2.87%
60D change
4.61%
MTD change
-5.42%
YTD change
-53.88%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DOCS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-29
Latest call per bank · past 12 months
Bank of America
Underperform$20.00
-2.2% vs priceGoldman Sachs
Neutral$24.00
+17.4% vs priceBarclays
Equal-Weight$20.00
-2.2% vs priceJefferies
Hold$19.00
-7.1% vs priceJP Morgan
Neutral$28.00
+36.9% vs priceWells Fargo
Equal-Weight$18.00
-12.0% vs priceMorgan Stanley
Overweight$35.00
+71.1% vs priceRBC Capital
Outperform$44.00
+115.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-29 | Bank of America | Downgrade | Buy → Underperform | $38.00 → $20.00 |
| 2026-05-15 | Goldman Sachs | Maintains | Neutral | $28.00 → $24.00 |
| 2026-05-15 | Barclays | Downgrade | Overweight → Equal-Weight | $38.00 → $20.00 |
| 2026-05-14 | Leerink Partners | Maintains | Outperform | $31.00 → $25.00 |
| 2026-05-14 | Jefferies | Downgrade | Buy → Hold | $51.00 → $19.00 |
| 2026-05-14 | Canaccord Genuity | Maintains | Buy | $34.00 → $30.00 |
| 2026-05-14 | JP Morgan | Maintains | Neutral | $33.00 → $28.00 |
| 2026-05-14 | Goldman Sachs | Maintains | Neutral | $28.00 → $24.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.5% below the 50-day MA ($20.98).
- Price vs 200-day MA: Trading 41.5% below the 200-day MA ($34.98).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.16) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($18.01) and high ($75.12).
DOCS Price Chart
Loading chart for DOCS…
Fundamentals
About Doximity, Inc.
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
More in Health Information Services
VEEV
Veeva Systems Inc.
$30B -16.6% YTD
BTSG
BrightSpring Health Services, I
$14B 94.7% YTD
TEM
Tempus AI, Inc.
$8B -27.7% YTD
HQY
HealthEquity, Inc.
$8B 3.3% YTD
HNGE
Hinge Health, Inc.
$6B 60.0% YTD
TXG
10x Genomics, Inc.
$6B 183.7% YTD
WAY
Waystar Holding Corp.
$4B -31.3% YTD
PRVA
Privia Health Group, Inc.
$3B 7.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.